Pulse Biosciences Releases Clinical Data on Thyroid Nodule Treatment

Pulse Biosciences announced clinical data on outcomes durability from the nPulse Vybrance Percutaneous Electrode System First-in-Human ablation study of benign thyroid nodules using nsPFA energy. The long-term follow-up from this study demonstrates significant and sustained volume reduction of treated benign thyroid nodules at 15-22 months, with no tissue regrowth and no serious adverse events. These data were presented at the North American Society for Interventional Thyroidology 2026 meeting, which took place in Portland, Oregon. Durable 15-22 month results with an average of 74% volume reduction of treated benign thyroid nodules with overwhelming patient satisfaction reported, Continued volume reduction improvements from 1 month through 22 months, No regrowth of nodules at 15-22 months. Patient-reported Cosmetic Satisfaction: 100% were Highly Satisfied at final follow-up. Patient-reported overall satisfaction: 95% were highly satisfied at final follow-up. No serious adverse events. No intranodular fibrosis detected on ultrasounds at 15-22 months. Potential for clinical durability of benign thyroid ablation. A total of 21 patients were subsequently monitored between 15 and 22 months to evaluate volume reduction trends over time.